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cedure and for each of the two years post-transplant and
reported in 2003 Canadian dollars. RESULTS: The mean costs
over all periods was $7706 for 876 persons undergoing kidney
transplant, $28,737 for 257 persons undergoing liver transplant,
$43,719 for 67 persons undergoing lung transplant and $31,152
for 133 persons undergoing heart transplant. The largest com-
ponent for all organs was the cost of the procedure and the initial
hospitalization. The mean (SD) costs in the ﬁrst and second post-
discharge years were, respectively, $21,552 (326) and $11,103
(1260) for kidney, $21,146 (1273) and $8090 (535) for liver,
$27,593 (4801) and $11,426 (1144) for lung and $22,588
(1044) and $9777 (520) for heart. Immunosuppresant medica-
tions comprised the largest single cost component during follow-
up. CONCLUSION: There was six-fold variation in direct
medical costs between the least and most expensive solid organ
transplant procedures. The variation in costs diminished between
programs over the ﬁrst and second years post-transplant.
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OBJECTIVES: To estimate the impact of the following Process
optimization (PO) measures implemented during 2002 on case-
related treatment costs (CRTC) in the ICU of a midsize German
hospital, from the hospital perspective: optimization of diagnos-
tic procedures, standardization of medical devices, improved
management of treatment courses, expansion of renal replace-
ment therapies, and replacement of fentanyl/midazolam (FM) 
by remifentanil/propofol (RP) throughout for analgosedation
within a standardized concept for mechanical ventilation.
METHODS: A retrospective cost-consequence analysis was per-
formed comparing 2 intervals: years 2000–2001 before and years
2003–2004 after PO. Data on baseline characteristics, treatment,
outcomes, and resource utilization (staff, laboratory, medical
need) of the ICU cases came from the routine documentation of
the ICU. Resources were valued in 2004 internal hospital prices.
Differences in CRTC and components between the intervals were
regarded signiﬁcant with a p value <0.05. RESULTS: There were
no signiﬁcant differences in baseline characteristics, distribution
of intensive treatment to monitoring, ventilation days, and case-
related mortality between the totals of 1704 and 2044 cases
treated before and after PO, respectively. CRTC, however, sig-
niﬁcantly dropped by 25% from €2435 before to €1815 after
PO, comprising staff expenses (from €1656 to €1238), labora-
tory cost (from €60 to €41), and cost for medical need (from
€718 to €536). The per-case cost for medical need signiﬁcantly
decreased although 2 of its 14 cost categories showed consider-
able increases: cost for renal replacement therapies were 2.9-fold
after PO due to expansion of this kind of treatment and cost 
for analgosedation were 2.1-fold after PO due to using RP
instead of FM. CONCLUSIONS: The whole PO improved 
the efﬁciency as indicated by signiﬁcantly decreased CRTC at
similar case-related mortality. Using RP throughout for anal-
gosedation of mechanically ventilated patients as an integral part
of a comprehensive PO strategy can result in savings of CRTC
in the ICU.
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OBJECTIVES: Although only 7 pharmacoeconomic and 6 
submission guidelines require partial or total budget impact
analyses (BIA), affordability is becoming a key issue to decision-
makers. Our aim was to review the published BIAs according to
different quality assessment criteria. METHODS: PubMed and
EMBASE were searched for articles with the search terms
“budget impact” or “budget analysis” limited to English lan-
guage. Relevant articles were abstracted by aim, funding, tech-
nology and various issues concerning the analyses. RESULTS: 16
studies were found between 2001 and 2006, the majority pre-
pared for pharmaceuticals, and from the US; however, 50% had
BIA only as complementary calculation to economic evaluations.
In the US, due the dominance of private health insurance, and
in France due to the submission requirements, all studies had BIA
as their main aim. Industry funding was stated for 63%;
however, industry afﬁliation was present for a further 13%. In
accordance with the aim of assisting NHS systems and insurance
companies determine affordability, the payer perspective was
chosen in all of the studies, complemented in a few cases by
patient or societal perspective. Direct medical costs (63%) or
only drug costs (19%) were assessed mostly for one year (44%).
Epidemiological data or rate of adoption was mainly based on
literature and assumptions. Results were reported by resource
type in only 6 (38%) studies, even though this would help to
realize a re-deployment of resources. The majority (56%) were
either cost-saving or had cost-saving scenarios. A sensitivity
analysis was done in only half of the studies for BIAs and in a
further 25% for economic evaluation only. CONCLUSIONS:
Although affordability is major issue in health care ﬁnance, BIAs
are still rare and frequently do not seem to generate independent
analyses. The quality of many studies also fails to reach desired
attributes.
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OBJECTIVES: Data from Sweden (Nyren 1992) shows the
annual frequency of consultations for functional dyspepsia (FD)
to be estimated at 47/1000 population with a costs estimated at
$US113,630/1000 population (1991 dollars). No published data
exists for US based employers on the costs associated with FD.
To assess the economic burden of FD associated with medical
costs and work loss from an employer perspective. METHODS:
A review was conducted using a person-centric database con-
taining costs from multiple large geographically diverse US based
employers between 2001–2004. Claims data included pharmacy,
medical, short- and long-term disability (STD, LTD), sick leave
(SL), and productivity measurements. Comparisons were made
between FD employees (ICD-9 code of 536.8) and employees
without FD. Data were compared for a 12-month period begin-
ning 3 months prior to the ﬁrst diagnosis of FD (the index date).
The average index date from the FD cohort was assigned for the
control group. Multiple regression and Markov modeling tech-
niques along with Charlson Co-Morbidity Index to adjust for
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variances. RESULTS: Data were available for 1669 employees
with FD and a control group of (274,206) employees without
FD. The FD group’s costs (per employee/year) were twice as high
($3676) summed across all direct medical and work absence
measures (P < 0.0001). The individual differences (favoring FD)
in medical and pharmacy costs were $3420 and $365, respec-
tively (both P < 0.0001). Work absence costs had differences of
$103 (SL, P < 0.0001), $104 (STD, P = 0.0370), $7 (LTD, P =
0.6551). Measured units of productivity were 2 units less/hour
with the FD group (P = 0.055). CONCLUSION: This study con-
ﬁrms earlier work from Sweden, but shows that in the US, FD
can be costly to employers. Physicians and patients need more
education on the ROME II criteria and how to integrate this
information into improving medical and pharmaceutical costs.
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OBJECTIVES: The risk of gastrointestinal ulcers is enhanced by
non-steroidal anti-inﬂammatory drugs (NSAID). Proton pump
inhibitors (PPI) are used for gastroprotection, but their effec-
tiveness has been documented only in few studies (Hooper et al.
BMJ 2004; 329:948–57). We therefore investigated in the gas-
troprotective effects of PPI on diclofenac-induced ulcer risk.
METHODS: A nested case control study was performed based
on claims data from a large German sickness fund. A cohort was
constructed consisting of all beneﬁciaries enrolled in the health
plan continuously from 2000 until 2004. Cases had an inpatient
treatment due to peptic ulcer starting at or after January 1st 2003
with the case onset being the index date. All other beneﬁciaries
were randomly allocated to an index date, and ten controls per
case were drawn. For the 90 days before the index date it was
checked, if diclofenac and/or PPI were dispensed. The inﬂuence
of diclofenac alone as well as with concomitant PPI prescription
on ulcer risk was analysed using logistic regression models.
RESULTS: We identiﬁed 979 cases and 10,319 controls in the
cohort of 752,613 beneﬁciaries. The stratiﬁed analysis accord-
ing to the prescription of diclofenac alone or in combination with
PPI showed that diclofenac prescriptions within the 90 days
before the index day increased the risk for hospitalization due 
to peptic ulcer signiﬁcantly (odds ratio (OR) 3.21; 95%CI
2.59–3.96; p < 0.001). The risk was reduced (OR 1.26; 95%CI
0.68–2.30; p = 0.46), if PPI were prescribed concomitantly with
diclofenac. The signiﬁcance of the PPI effect was demonstrated
by inserting an interaction term in a regression model without
stratiﬁcation, where a risk reduction of 63% (OR 0.37; 95%CI
0.18–0.74; p = 0.005) was found. CONCLUSION: The con-
comitant prescription of PPI and diclofenac decreases the hospi-
talization risk due to peptic ulcer thus supporting the use of PPI
as gastroprotective agents.
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OBJECTIVES: To conduct an economic evaluation of terli-
pressin and octreotide used in the UK in the treatment of Bleed-
ing Oesophageal Varices (BOV). METHODS: Efﬁcacy results
from Cochrane meta-analyses were used. Baseline course of
disease and health-related utility (HRU) were retrieved from
published sources. Hospitalization related data were extracted
from HODaR, a large longitudinal database. Costs were
obtained from published sources, BNF and HODaR. A discrete
event simulation model was coded in VBA with the following
transition states: bleeding, no bleeding, no bleeding post-TIPS,
post-salvage surgery, and death. Weibull curves were ﬁtted to
estimate baseline survival, re-bleeding rates, and failure to
control bleeding. Simulations were run for up to ﬁve years since
initial bleeding. Prices were in UK£2005 and a discount rate of
3.5% was applied to costs and beneﬁts. Sensitivity analysis was
run with C++ dll engine. RESULTS: Terlipressin was found 
to be cost-effective with baseline values of ICER at 1 year
£5263/QALY (£3865/LYG) versus octreotide and £5618/QALY
(£4136/LYG) versus placebo. In baseline analysis octreotide was
not cost-effective against placebo. Based on deterministic and
probabilistic sensitivity analyses terlipressin remained cost-effec-
tive when compared to octreotide and placebo; it was cost-saving
for some of the varied input values. Distribution of ICER values
demonstrated cost-effectiveness of octreotide versus placebo, but
on CEAC curve, probability of cost-effectiveness of octreotide
and placebo were of the same magnitude: 24.0% and 23.4%,
respectively, at £20,000/QALY. The results were sensitive to
utility variables, but were generally robust and independent of
assumptions regarding baseline risk. Total Expected Value of
Perfect Information at 1 year varied from £928 to £220 per
patient depending on the range of variation of input variables.
CONCLUSIONS: Terlipressin is cost-effective when compared
to octreotide and placebo for the treatment of BOV in cirrhotic
patients. Further analysis is needed to establish cost-effectiveness
of octreotide versus placebo.
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OBJECTIVES: To assess the cost-effectiveness of two commonly
used triple therapies for H. pylori eradication in a public hospi-
tal in Hong Kong. METHODS: A prospective observational
design was adopted. Two cohorts of patients attending the GI
Specialty Clinic at the Prince of Wales Hospital with endoscop-
ically conﬁrmed non-ulcer dyspepsia and H. pylori positive con-
ﬁrmed by CLO Test were recruited. Informed consent from
patients and ethic approval from hospital were obtained. The
patients were consecutively recruited to receive esomeprazole +
amoxicillin + clarithromycin (EAC) or rabeprazole + amoxicillin
+ clarithromycin (RAC) therapies. One-week treatment was
given and urea breath test was performed after 4 weeks to
conﬁrm if eradication was successful. Initial treatment failures
were given quadruple rescue therapy (metronidazole + esomepra-
zole + danol + tetracycline). All health care resources including
clinic visits, laboratory procedures, medications, and profes-
sional services were recorded. RESULTS: One-hundred and three
and 96 patients were recruited to the EAC and RAC groups
respectively. The demographic characteristics were not signiﬁ-
cantly different except the RAC group had a lower rate of drink-
ing and smoking habits. The success rates for eradication for the
EAC and RAC groups were 88.5% and 85.4% respectively (p =
NS). The cost/successful eradication for EAC group and RAC
group was USD846 and USD843.7 respectively. The cost/suc-
cessful eradication after quadruple therapy was USD871 and
